Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Melanoma, Non-Melanoma), By Test Type (Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests) By End-use, By Region, And Segment Forecasts, 2025 - 2033
Description
Skin Cancer Diagnostics Market Summary
The global skin cancer diagnostics market size was estimated at USD 9.58 billion in 2024 and is projected to reach USD 15.67 billion by 2033, growing at a CAGR of 5.7% from 2025 to 2033. The integration of artificial intelligence, technological advancements, and patient preference for non-invasive diagnostics drives the growth.
Furthermore, increased awareness about skin cancer, advancements in AI-based diagnostic tools, and initiatives promoting early detection, rising incidence, particularly in sun-exposed regions, are expected to drive the market growth. For instance, according to the American Cancer Society, invasive melanoma accounts for only 1% of all skin cancer cases, and in 2024, an estimated 100,640 new cases of invasive and 99,700 cases of in situ melanoma were diagnosed in the U.S. Partnerships between healthcare providers and tech companies further support this growth by enhancing accessibility and accuracy of diagnoses.
Furthermore, advanced technologies such as AI-enabled product approvals are driving the growth of the market. For instance, in January 2024, the FDA approved the first AI-powered skin cancer diagnostic tool, namely the DermaSensor device. Further, DermaSensor provides quantitative, point-of-testing identification for skin cancer, including melanoma, squamous cell carcinoma, and basal cell carcinoma. Also, the DermaSensor device uses artificial intelligence (AI)-powered spectroscopy in order to identify cellular and subcellular characteristics of lesions.
Modern machine learning techniques rely on extensive datasets to identify patterns useful for classification, with diagnostic imaging being a particularly promising area for AI research. Moreover, skin cancer detection, in particular, is an attractive test type for AI due to the subjective nature of clinical and dermoscopic image interpretation. Also, AI-assisted diagnosis offers advantages such as improved access to specialist expertise, which is often scarce in many regions, leading to long waiting times for specialist appointments. There is growing optimism that AI-based systems could offer greater consistency and higher accuracy than human experts.
Global Skin Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global skin cancer diagnostics market report based on cancer type, test type, end use, and region:
The global skin cancer diagnostics market size was estimated at USD 9.58 billion in 2024 and is projected to reach USD 15.67 billion by 2033, growing at a CAGR of 5.7% from 2025 to 2033. The integration of artificial intelligence, technological advancements, and patient preference for non-invasive diagnostics drives the growth.
Furthermore, increased awareness about skin cancer, advancements in AI-based diagnostic tools, and initiatives promoting early detection, rising incidence, particularly in sun-exposed regions, are expected to drive the market growth. For instance, according to the American Cancer Society, invasive melanoma accounts for only 1% of all skin cancer cases, and in 2024, an estimated 100,640 new cases of invasive and 99,700 cases of in situ melanoma were diagnosed in the U.S. Partnerships between healthcare providers and tech companies further support this growth by enhancing accessibility and accuracy of diagnoses.
Furthermore, advanced technologies such as AI-enabled product approvals are driving the growth of the market. For instance, in January 2024, the FDA approved the first AI-powered skin cancer diagnostic tool, namely the DermaSensor device. Further, DermaSensor provides quantitative, point-of-testing identification for skin cancer, including melanoma, squamous cell carcinoma, and basal cell carcinoma. Also, the DermaSensor device uses artificial intelligence (AI)-powered spectroscopy in order to identify cellular and subcellular characteristics of lesions.
Modern machine learning techniques rely on extensive datasets to identify patterns useful for classification, with diagnostic imaging being a particularly promising area for AI research. Moreover, skin cancer detection, in particular, is an attractive test type for AI due to the subjective nature of clinical and dermoscopic image interpretation. Also, AI-assisted diagnosis offers advantages such as improved access to specialist expertise, which is often scarce in many regions, leading to long waiting times for specialist appointments. There is growing optimism that AI-based systems could offer greater consistency and higher accuracy than human experts.
Global Skin Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global skin cancer diagnostics market report based on cancer type, test type, end use, and region:
- Cancer Type Outlook (Revenue, USD Million; 2021 - 2033)
- Melanoma
- Non-Melanoma
- Test Type Outlook (Revenue, USD Million; 2021 - 2033)
- Dermatoscopy
- Skin Biopsy
- Lymph node biopsy
- Imaging Tests
- Others
- End Use Outlook (Revenue, USD Million; 2021 - 2033)
- Hospital and Clinics
- Laboratories
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Kuwait
- UAE
Table of Contents
125 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Cancer Type
- 1.2.2. Test Type
- 1.2.3. End Use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Scope & Assessment
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Cancer type and test type outlook
- 2.2.2. End use outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Skin Cancer Diagnostics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Technological advancements
- 3.2.1.2. Integration of artificial intelligence
- 3.2.1.3. Patient preference for non-invasive diagnostics
- 3.2.2. Market restraint analysis
- 3.2.2.1. High Cost of Diagnostic Imaging
- 3.3. Skin Cancer Diagnostics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- Chapter 4. Skin Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis
- 4.1. Global Skin Cancer Diagnostics Market: Cancer Type Dashboard
- 4.2. Global Skin Cancer Diagnostics Market: Cancer Type Movement Analysis
- 4.3. Global Skin Cancer Diagnostics Market by Cancer Type, Revenue
- 4.4. Melanoma
- 4.4.1. Melanoma market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5. Non-Melanoma
- 4.5.1. Non-Melanoma market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 5. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis
- 5.1. Global Skin Cancer Diagnostics Market: Test Type Dashboard
- 5.2. Global Skin Cancer Diagnostics Market: Test Type Movement Analysis
- 5.3. Global Skin Cancer Diagnostics Market by Test Type, Revenue
- 5.4. Dermatoscopy
- 5.4.1. Dermatoscopy market estimates and forecasts for 2021 to 2033 (USD Million)
- 5.5. Skin Biopsy
- 5.5.1. Skin Biopsy market estimates and forecasts for 2021 to 2033 (USD Million)
- 5.6. Lymph node biopsy
- 5.6.1. Lymph node biopsy market estimates and forecasts 2021 to 2033 (USD Million)
- 5.7. Imaging Tests
- 5.7.1. Imaging Tests market estimates and forecasts 2021 to 2033 (USD Million)
- 5.8. Others
- 5.8.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)
- Chapter 6. Skin Cancer Diagnostics Market: End Use Estimates & Trend Analysis
- 6.1. Global Skin Cancer Diagnostics Market: End Use Dashboard
- 6.2. Global Skin Cancer Diagnostics Market: End Use Movement Analysis
- 6.3. Global Skin Cancer Diagnostics Market by End Use, Revenue
- 6.4. Hospital and Clinics
- 6.4.1. Hospital and Clinics market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5. Laboratories
- 6.5.1. Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6. Others
- 6.6.1. Others Analysis market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 7. Skin Cancer Diagnostics Market: Regional Estimates & Trend Analysis by Cancer Type, Test Type, and End Use
- 7.1. Regional Dashboard
- 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 7.3. North America
- 7.3.1. U.S.
- 7.3.1.1. Key country dynamics
- 7.3.1.2. Regulatory framework/ reimbursement structure
- 7.3.1.3. Competitive scenario
- 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 7.3.2. Canada
- 7.3.2.1. Key country dynamics
- 7.3.2.2. Regulatory framework/ reimbursement structure
- 7.3.2.3. Competitive scenario
- 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 7.3.3. Mexico
- 7.3.3.1. Key country dynamics
- 7.3.3.2. Regulatory framework/ reimbursement structure
- 7.3.3.3. Competitive scenario
- 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework/ reimbursement structure
- 7.4.1.3. Competitive scenario
- 7.4.1.4. UK market estimates and forecasts for 2021 to 2033 (USD Million)
- 7.4.2. Germany
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework/ reimbursement structure
- 7.4.2.3. Competitive scenario
- 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.3. France
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework/ reimbursement structure
- 7.4.3.3. Competitive scenario
- 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.4. Italy
- 7.4.4.1. Key country dynamics
- 7.4.4.2. Regulatory framework/ reimbursement structure
- 7.4.4.3. Competitive scenario
- 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.5. Spain
- 7.4.5.1. Key country dynamics
- 7.4.5.2. Regulatory framework/ reimbursement structure
- 7.4.5.3. Competitive scenario
- 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.6. Norway
- 7.4.6.1. Key country dynamics
- 7.4.6.2. Regulatory framework/ reimbursement structure
- 7.4.6.3. Competitive scenario
- 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.7. Sweden
- 7.4.7.1. Key country dynamics
- 7.4.7.2. Regulatory framework/ reimbursement structure
- 7.4.7.3. Competitive scenario
- 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.8. Denmark
- 7.4.8.1. Key country dynamics
- 7.4.8.2. Regulatory framework/ reimbursement structure
- 7.4.8.3. Competitive scenario
- 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/ reimbursement structure
- 7.5.1.3. Competitive scenario
- 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.2. China
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/ reimbursement structure
- 7.5.2.3. Competitive scenario
- 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.3. India
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework/ reimbursement structure
- 7.5.3.3. Competitive scenario
- 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.4. Australia
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework/ reimbursement structure
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.5. South Korea
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework/ reimbursement structure
- 7.5.5.3. Competitive scenario
- 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.6. Thailand
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework/ reimbursement structure
- 7.5.6.3. Competitive scenario
- 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework/ reimbursement structure
- 7.6.1.3. Competitive scenario
- 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.2. Argentina
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework/ reimbursement structure
- 7.6.2.3. Competitive scenario
- 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework/ reimbursement structure
- 7.7.1.3. Competitive scenario
- 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework/ reimbursement structure
- 7.7.2.3. Competitive scenario
- 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7.3. UAE
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework/ reimbursement structure
- 7.7.3.3. Competitive scenario
- 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Regulatory framework/ reimbursement structure
- 7.7.4.3. Competitive scenario
- 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2024
- 8.3.4. Castle Bioscience
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. DermTech
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. bioMérieux Inc.
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. FOUNDATION MEDICINE, INC.
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. DermaSensor, Inc.
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. F Hoffmann-La Roche Ltd
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. NeoGenomics Laboratories
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Product benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. Quest Diagnostics Incorporated
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Product benchmarking
- 8.3.11.4. Strategic initiatives
- 8.3.12. SkylineDx
- 8.3.12.1. Company overview
- 8.3.12.2. Financial performance
- 8.3.12.3. Product benchmarking
- 8.3.12.4. Strategic initiatives
- 8.3.13. Abbott
- 8.3.13.1. Company overview
- 8.3.13.2. Financial performance
- 8.3.13.3. Product benchmarking
- 8.3.13.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
